2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
Why now
Thesis: Encouraging CAR-T data, early and narrow
Catalyst to watch: Peer review and larger trials
Main risk: Retrospective analysis limits conclusions
Why it matters
CAR-T persistence data supports cell-therapy durability but is early-stage and company-specific.
Details
At 2026 IMS: Updated FUMANBA-1 Data from IASO Bio's Equecabtagene Autoleucel (Fucaso) Demonstrate In Vivo Durable Persistence of CAR-T Cells Associated with Sustained MRD-Negativity and Delayed Disease Progression — Retrospective analysis of 102 patients from the pivotal FUMANBA-1 study...
Sources
- prnewswire · 2026-09-25 14:54 UTC